Oral Transmucosal Drugs Market:
Introduction
According to the report, the global oral transmucosal drugs
market was
valued over US$ 14 Bn in 2020 and is
projected to expand at a CAGR of ~6% from 2021 to 2031.
Rise in prevalence of neurological disorders and chronic diseases, increase in
geriatric population, and adoption of novel drug delivery systems are the key
factors anticipated to drive the global oral transmucosal drugs market during
the forecast period.
North America held a major share of the global oral transmucosal
drugs market in 2020, due to easy availability of products,
presence of a large number of suppliers, and higher penetration of oral transmucosal
drugs compared to other regions. The oral transmucosal drugs market in Asia
Pacific is expected to expand at a high CAGR of 7.9% from 2021 to 2031 due
to rise in healthcare expenditure and increase in geriatric population.
Request a Sample of Oral Transmucosal Drugs Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82339
Increase in Incidence of
Autoimmune Disorders, Respiratory Problems, Cancer, Mucositis to Drive Global
Market
The global oral transmucosal drug market is projected to grow at a
rapid pace during the forecast period, owing to increase in incidence of
autoimmune disorders, respiratory problems, cancer, and mucositis. The number
of people affected by autoimmune disorders, respiratory problems, oral cancer,
and mucositis continues to rise across the world. This escalates the need of
oral transmucosal drugs, as these are able to prevent gastrointestinal degradation
and provide rapid onset of action.
Cancer is one of the leading causes of death globally. The number
of people being affected by different types of cancer increases every year.
According to the WHO, an estimated 70% of deaths due to cancer occur in lower-
and middle-income countries. The number of patients with different chronic
diseases is rising rapidly across the world. This is likely to increase
pre-surgical procedures such as medication, which, in turn, is anticipated to
propel the global oral transmucosal drugs market in the near future.
Enquiry Before Buying Oral Transmucosal Drugs Market
Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=82339
High Preference for Tablets
In terms of type, the global oral transmucosal drugs market has
been classified into tablets, buccal films, liquid & spray, gels, and
others. The tablets segment dominated the global oral transmucosal drugs market
in 2020,
and the trend is projected to continue during the forecast period. The
segment's dominance can be attributed to high demand for buccal tablets,
sublingual tablets, and lozenges in the market.
Buccal Drugs to Drive Global
Market
Based on route of penetration, the global oral transmucosal drugs
market has been categorized into sublingual mucosa, buccal mucosa, gingival
tissues, and palatal tissues. The buccal mucosa segment held major share of the
global oral transmucosal drugs market in 2020. The
segment’s dominance can be attributed to availability of a large number of
buccal drugs, as buccal mucosa offers higher permeability and faster onset of
action.
Request For Discount - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=82339
Retail Pharmacies to be Major
Distribution Channel
In terms of distribution channel, the global oral transmucosal
drugs market has been divided into hospital pharmacies, retail pharmacies, and
online pharmacies. The retail pharmacies segment dominated the market in 2020,
owing to high penetration of retail pharmacies or community pharmacies for
dispensing of oral transmucosal drugs.
Rise in Incidence of Acute Pain
Based on indication, the global oral transmucosal drugs market has
been segregated into cardiovascular disorders, acute pain management, sedation,
erectile dysfunctions, diabetes, and others. The acute pain management segment
dominated the market in 2020 due to increase in incidence of acute
pain across the world. An article published by the Physiopedia in 2018 stated
that one in five adults suffer from pain and one in 10 adults are diagnosed
with chronic pain each year globally.
North America to Dominate Global
Market, Asia Pacific to Offer Significant Opportunities
In terms of region, the global oral transmucosal drugs market has
been segmented into North America, Europe, Latin America, Asia Pacific, and
Middle East & Africa. North America is projected to account for a leading
share of the global oral transmucosal drugs market during the forecast period.
High awareness about the benefits of oral transmucosal drugs and availability
of the drugs are the major factors driving the market in the region.
The oral transmucosal drugs market in Asia Pacific is likely to
grow at a rapid pace in the near future. Rise in R&D investment and surge
in healthcare expenditure are anticipated to drive the market in the region.
Additionally, increase in geriatric population is likely to propel the oral
transmucosal drugs market in the region. According to the world population
prospects 2019, the proportion of geriatric population would increase from
the 28% in 2019 to 38% by 2050 in
Japan.
Buy now Oral Transmucosal Drugs Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=82339<ype=S
Growth Strategies of Key Players
Key players operating in the global oral transmucosal drugs market
are LTS Lohmann Therapie-Systeme AG, Soligenix, ZIM Laboratories
Limited, Access Pharmaceutical Inc., C.L Pharm, Seoul
Pharmaceuticals, Cure Pharmaceutical, Aquestive Therapeutics,
Inc., Solvay S.A., NAL Pharma, IntelGenx Corp., Izun Pharmaceuticals,
Eisai Co., Ltd, AstraZeneca, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc.,
Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Mylan N.V., and
Bristol-Myers Squibb Company.
These companies engage in research & development activities to
develop novel products in order to expand product offerings and customer base.
For instance, in January 2021, Cure Pharmaceutical received the U.S. FDA
approval for CUREfilm Blue for the treatment of erectile dysfunction (ED). It
increased the commercial opportunity for Cure Pharmaceutical in the U.S.
More
Trending Reports by Transparency Market Research:
https://www.prnewswire.com/news-releases/new-engineering-approaches-in-vascular-grafts-market-expands-horizon-of-endovascular-surgeries-synthetic-products-attract-rd-tmr-301278115.html
https://www.prnewswire.com/news-releases/global-optical-lens-edger-market-to-thrive-on-growing-popularity-of-digital-camera-market-projected-to-clock-impressive-6-5-cagr-from-2018--2026--tmr-301283241.html
https://www.prnewswire.com/news-releases/manufacturers-in-injection-pen-market-aimed-at-improving-diabetes-care-to-propel-constant-design-advances-by-2030-global-valuation-to-climb-to-us-6-bn-tmr-301287473.html
About Us
Transparency Market Research is a global market intelligence
company providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. Our experienced team
of analysts, researchers, and consultants use proprietary data sources and
various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team
of research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability, Transparency Market
Research employs rigorous primary and secondary research techniques in
developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
